Strategies for Raising Venture Capital or Securing Additional Financing: Tips for Biotech Executives

With the volatility of public markets in 2022, many companies have considered additional raises from venture funds or alternative financing methods.  According to the Silicon Valley Bank (SvB) midyear report, biotech fundraising in the first half of 2022 was on pace with 2020 despite a record-breaking year in 2021. Join this session to review recent data from SvB on venture trends and therapeutic and platform areas of growth. Investors and other executives will then provide their outlook of 2023 financing opportunities as the sector navigates a changing macroeconomic environment.